Piper Sandler analyst Jessica Tassan raised the firm’s price target on Evolent Health to $51 from $44 and keeps an Overweight rating on the shares. The analyst assume the Magellan Specialty Health acquisition closes in the first half of 2023 and introduced pro forma estimates. She views Evolent’s acquisitions as "transformational."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVH: